Abionyx News and Activities
Presence
Abionyx is a biotechnology company that develops therapies based on HDL and apolipoprotein science. Its products and services focus on rare diseases and intensive care needs for hospitals, researchers, and healthcare partners.
Abionyx products and services overview:
- Biologic therapies
- Rare disease treatments
- Critical care therapies
- Drug research services
Revenue: ~$2 million
Employees: 25
Headquarters: Toulouse, France
Abionyx is one of the...
Abionyx is a company listed under the stock ticker ABNX (FR).
Executives
View the org chart displaying its 11 main executives
Most searched biographies at Abionyx
- Cyrille Tupin, Chief Executive Officer and Director
- Emmanuel Huynh, Chairman of the Board
- Jean-Gérard Galvez, Director
Create your alert
to follow the executive moves at Abionyx.
Biotechnology
Abionyx has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
- NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (posted on June 1 2026)..
Popular contacts in Biotechnology
News
Press releases by Abionyx
- CERENIS - THERAPEUTICS - Positive results from the CER-209 Phase I Single Dose Tolerance study for NAFLD and NASH
- CERENIS - THERAPEUTICS - Publication of 2016 Registration Document
- CERENIS - THERAPEUTICS - Cash position and update on clinical developments for Q1 2017
Social media about Abionyx
- Abionyx on Wikipedia, Google News & Yahoo Finance
- Abionyx on LinkedIn, X (Twitter) & YouTube
